VRX-Valeant Pharma Stock Research, Ratings, and Analysis

Valeant Pharma (vrx) Stock Research

Last Updated by Anonymous | Update This Page Now

►Summary | Profile | News | Chart | SWOT | Cash Flow | Comps | Buffett | WACC

Company Description: Valeant Pharmaceuticals International, founded in 1960, develops, manufactures, and markets specialty pharmaceutical products. It primarily offers prescription pharmaceutical products in the areas of neurology, dermatology, and infectious diseases. It also provides products in the areas of neuromuscular disorders, cancer, cardiovascular disease, diabetes, and psychiatric disorders, and produces a skin care line for various skin disorders. Headquartered in Aliso Viego, California, the company markets its hundreds of branded products to physicians, hospitals, pharmacies, and wholesalers in the United States and abroad. Update

Market Research Update

Health Care Industry Research & Analysis: The health care industry depends on the care of health-related services by professionals for the benefit of patients. Medical device markers, insurance companies, pharmaceutical drug developers and government institutions are major participants in the treatment of sick, injured and disabled patients. Health Care Trading Strategy: Health Care stocks tend to be less sensitive to economic changes. Look for undervalued health care investments at any point in the business cycle when stock prices are low. However, biotech, employment staffing and insurance companies may all decrease during recessions for different reasons. Government intervention is another important factor in health care investments, since government spending in health care is a very large portion of overall health care spending. When governments change spending plans, different sub-sectors in the industry are significantly affected. Upward sloping stock charts and financial news may indicate a selling opportunity while the opposite means that stocks are becoming undervalued.

Industry Sub Sector: . Valeant Pharma is a dominant industry leader due to its personnel, experience and financial strengths. Industry leaders are difficult to compete against, which decreases business and investor risks. The market is quickly expanding. This lowers the threat of direct competition and increases Valeant Pharma's profits.

Market Challenges: Opportunities: Solutions:

Strategy Analysis Update

Valeant Pharma's business strategy is to keep things simple. Clearly-defined strategies lower business risks by staying within their areas of expertise. Valeant Pharma possesses significant barriers to entry that slows competitive threats and increases profits. Valeant Pharma's strategy is to accomplish clear, attainable, and challenging goals. This focus increases company value and long-term investor returns. A culture that experiments produces better long term value. Valeant Pharma's experimentations yield new products and services that outpace competitive threats. Valeant Pharma's strategy is to continuously improve. This helps to fend against competitive threats and increases shareholder returns.

Strategy: Valeant Pharma targets customers who have very specific needs and with solutions that are difficult to replicate. (read more). Competitive Advantages:

Financial Analysis Update

Valeant Pharma has consistent operating results. This lowers the risk that Valeant Pharma will suddenly have difficulty and it increases investor confidence in the value they place on each share. Complicated financial statements lower Valeant Pharma's value, because it increases the risk of fraud and lowers investor confidence.

Current Revenue Sources: Future Revenue Sources: